manilatimes7h
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Hosted on MSN14h
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
Agios Pharmaceuticals AGIO announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label ...
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...
The Financial Express17h
USFDA gives nod to Lupin’s generic formulation to treat eye issues
Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S.
Pharmabiz19h
US FDA clears Solid Biosciences’ IND application for SGT-212 to treat neurologic & cardiac manifestations of Friedreich’s ataxia
Charlestown, Massachusetts Thursday, January 9, 2025, 14:30 Hrs [IST] ...